Last reviewed · How we verify
NCT03638973
Comparison of Sample Biopsy Using Scalpel or Er:YAG Laser
NA trial testing Biopsy in Laser Burn in 44 participants. Status unknown.
1 November 2019
Quick facts
| Lead sponsor | University of Zurich |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 1 November 2018 |
| Primary completion | 1 November 2019 |
| Estimated completion | 1 November 2020 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Biopsy — full drug profile →
Conditions studied
- Laser Burn — all drugs for Laser Burn →
- Gingival Disease — all drugs for Gingival Disease →
- Biopsy Wound — all drugs for Biopsy Wound →
Sponsor
University of Zurich
Who can join
Adults 18 to 100, any sex, with Laser Burn or Gingival Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
For certain changes in the oral mucosa a histopathological examination of the affected tissue is indicated to confirm the diagnosis. The gold standard is the biopsy by scalpel. The aim of this study is to compare the alternative method of tissue sampling using the erbium doped yttrium aluminium garnet (Er:YAG) laser with the gold Standard.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03638973
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biopsy
Trials testing the same drug.
- NCT06675123 — Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lym · Phase 1 · recruiting
- NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT06860815 — Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Br · Phase 2 · recruiting
- NCT05741164 — Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory · Phase 2 · not yet recruiting
Other University of Zurich trials
Trials by the same sponsor.
- NCT07485699 — Soy Processing and Food Allergy · NA · not yet recruiting
- NCT07516912 — Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland · not yet recruiting
- NCT07473115 — Individualized Analgesia in the Intensive Care Unit With a New Pain Assessment Bundle and Protocolized Analgesia Adjustm · not yet recruiting
- NCT07524023 — Emotional-distress-based Integrated Care Programme in Patients With Stable COPD · NA · recruiting
- NCT06481982 — Value of Advanced MRI Techniques in the Assessment of Endometriosis · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03638973 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Zurich
- Last refreshed: 12 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03638973.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing